Shots: The P-III study evaluates the efficacy, safety & immunogenicity of BCD-021 (q3w for 6 cycles) vs reference Avastin + paclitaxel & carboplatin in 357 patients with stage IIIB or IV nonsq. […]readmore
Shots: The P-III study evaluates the cardiac safety profiles & efficacy of Ontruzant vs reference trastuzumab in 367 patients with HER2 positive early or LA BC for 4yrs. after randomization […]readmore
Shots: The AVT02-GL-302 study evaluates AVT02 in 568 patients at ~30 centers in the EU. Patients were randomized into either of the two arms of the switching module: The first […]readmore
Shots: The P-III study evaluates Byooviz (0.5 mg, IVT) vs ranibizumab in 634 patients with nAMD. The results will be presented at EURETINA 2021 The 1EPs are changed from baseline […]readmore
Shots: The 1st P-I study evaluates MSB11456 as SC formulation vs US-Actemra/EU-RoActemra & 2nd P-I study evaluate MSB11456 vs Actemra as IV formulation in patients with moderately to severely active RA […]readmore
Shots: Bio-Thera to receive $20M up front and $130M as development and commercial milestones and will be responsible for the development, manufacturing, and supply of BAT2206 Hikma get exclusive rights […]readmore
Shots: Nora collaborates with a biopharmaceutical partner to obtain the commercial rights for a biosimilar drug The collaboration will support both private insurers and public formularies by reducing the costs […]readmore
Shots: The EC has approved Byooviz (biosimilar, ranibizumab) in the EU for the treatment of Ophthalmic disease Lucentis is used to treat ophthalmic disease & macular degeneration. Byooviz marks the […]readmore
Shots: The PATRO Children, post marketing surveillance study evaluates biosimilar rhGH (Omnitrope) vs reference rhGH (Genotropin) in 348 children with TS at 130 centers across EU. In this study, 81.6% […]readmore
Shots: DCGI has granted the marketing authorization to Enzene’s Romiplostim biosimilar for the treatment of chronic ITP in adults The company provides all the three dosage strengths of the product […]readmore
Copyright © 2020 Digiqole. All Right Reserved.